European life Sciences VC Firm Medicxi Closes €500M Fund V

The fund received more commitments than expected from existing investors and several new institutional investors.

Medicxi V will follow the firm’s asset-focused investment approach. The fund will support drug developers and founders working on single-asset and focused biotech projects. It will also invest in companies already in the Medicxi portfolio, as well as others that follow the same model.

Through Medicxi V, the firm plans to help advance drug programs and bring them closer to clinical and commercial progress for patients.

Read Also - Copenhagen’s Flatpay Raises €146.5M, Becomes Denmark’s Fastest Unicorn at $1.7B

Francesco De Rubertis, co-founder and Partner at Medicxi, says, “Medicxi’s longstanding success has been founded on its unique ties to leading global pharmaceutical companies and its world-class team of drug hunters and clinicians. The new €500M fund will enable Medicxi to provide the critical capital, expertise and experience to deliver transformative therapies for patients.”

Medicxi has announced that Shyam Masrani has been promoted to Partner. Masrani has managed the firm’s work with Merus and ProfoundBio and serves on the boards of Acera Therapeutics, T-CypherBio, and Petalion Therapeutics.

Fund V will be managed by Francesco De Rubertis, Giovanni Mariggi, Nick Williams, and Masrani.

Giovanni Mariggi, co-founder and Partner at Medicxi, says, “Medicxi’s differentiated, capital-efficient investment strategy is rapidly scaling, and we have now raised six funds in the last 10 years, totalling over €2B.”

“We are extremely grateful for the support that we have received from our existing and new limited partners, and we are excited to continue investing in cutting-edge science and accelerating the discovery of life-changing medicines for patients.”

Founded in 2016, Medicxi is an investment firm focused on healthcare. Its goal is to create and support companies that work across the entire drug development process.

The firm builds on more than 20 years of experience in drug development and company formation. It invests in programs at both early and later stages and supports products designed to meet specific patient needs.

Since its last fundraise, Medicxi has created 16 companies and achieved over 20 clinical readouts in its portfolio. The firm has also generated more than $1 billion from exits and listings. Notable outcomes include Vaxcyte, Merus, and Abivax, as well as the acquisitions of ViceBio by Sanofi, Versanis Bio by Eli Lilly, and ProfoundBio by Genmab.

About Medicxi

Medicxi is a Life Sciences venture capital firm with offices in London, St. Helier and Geneva. Founded to support biotech innovation, it invests across the full drug development process, backing companies from early-stage programs to advanced clinical projects aiming to create therapies that address critical patient needs worldwide.